Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-280: capivasertib + docetaxel versus placebo + docetaxel in metastatic castration-resistant prostate cancer
MOH_2023-01-22_012296Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2023-01-22_012296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-22_012296.